Rani Therapeutics (RANI) Stock Price, News & Analysis

Company Overview

Rani Therapeutics (NASDAQ: RANI) is a clinical-stage biopharmaceutical company specializing in the development of oral delivery technologies for large-molecule drugs. Headquartered in San Jose, California, the company is pioneering a proprietary robotic pill platform designed to enable the non-invasive administration of biologics that traditionally require injection. By leveraging its innovative RaniPill™ capsule, Rani Therapeutics seeks to address patient compliance and improve the therapeutic reach of peptides, proteins and antibodies.

The company’s flagship technology integrates a swallowable capsule equipped with a micro-needle and controlled release mechanism. Upon reaching the small intestine, the capsule deploys its delivery system to inject the active molecule directly into the intestinal wall, facilitating systemic absorption. Rani Therapeutics is advancing several programs through preclinical and early clinical stages, with a focus on oral formulations of GLP-1 agonists for metabolic diseases and anti-TNF therapies for autoimmune disorders.

Founded in 2012 by serial entrepreneur Mir Imran, Rani Therapeutics emerged from InCube Labs with a vision to transform the administration of injectable medicines. Over the years, the company has built a cross-functional team of experts in drug formulation, medical device engineering and clinical development. Rani Therapeutics maintains research facilities in Silicon Valley and the East Coast, positioning itself to collaborate with academic institutions and pharmaceutical partners around the world.

Under the leadership of Mir Imran as chairman and CEO, Rani Therapeutics has raised multiple rounds of venture and public financing to support its pipeline advancement and manufacturing scale-up. With an eye toward global commercialization, the company is exploring strategic partnerships to bring its oral biologics platform to patients across North America, Europe and Asia. By offering an alternative to injectable regimens, Rani Therapeutics aims to redefine patient experience and broaden the impact of biologic therapies.

Key Stats

• Today's Range: $0.63 to $0.68
• 50-Day Range: $0.48 to $1.08
• 52-Week Range: $0.46 to $4.19
• Volume: 520,579 shs
• Average Volume: 947,964 shs
• Market Capitalization: $37.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Buy

Rani Therapeutics Stock Analysis - MarketRank™

Rani Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 739th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Rani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rani Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rani Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rani Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rani Therapeutics has a P/B Ratio of 10.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.19% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Rani Therapeutics has recently increased by 4.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rani Therapeutics does not currently pay a dividend.

Dividend Growth

Rani Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.19% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Rani Therapeutics has recently increased by 4.13%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

Rani Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Rani Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rani Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.42% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.19% of the stock of Rani Therapeutics is held by institutions.

RANI Stock Analysis - Frequently Asked Questions

How have RANI shares performed this year?

Rani Therapeutics' stock was trading at $1.37 at the beginning of the year. Since then, RANI stock has decreased by 53.0% and is now trading at $0.6440.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, hitting analysts' consensus estimates of ($0.22). The business had revenue of $0.20 million for the quarter.

When did Rani Therapeutics IPO?

Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rani Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RANI
• CIK: 1856725
• Web: www.ranitherapeutics.com
• Phone: 408-457-3700
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rani Therapeutics: $7.33
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +1,038.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.02 million
• Net Margins: N/A
• Pretax Margin: -4,545.25%
• Return on Equity: -1,258.76%
• Return on Assets: -80.52%

Debt

• Debt-to-Equity Ratio: 2.75
• Current Ratio: 0.88
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $1.03 million
• Price / Sales: 39.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 10.73

Miscellaneous

• Outstanding Shares: 63,210,000
• Free Float: 34,714,000
• Market Cap: $40.71 million
• Optionable: Optionable
• Beta: -0.02